Sales Support
U.S.:+1-415-871-0703
U.K.:+44-203-289-4040
AUS.: +61-2-4786-0457
INDIA:+91-848-285-0837
Contact Us
We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
Healthcare and Pharmaceuticals industry

Neuroendocrine Tumor Treatment market 2020 BY MANUFACTURERS, REGIONS, TYPE AND APPLICATION, FORECAST TO 2026

  • Purchase Options

 
Report Description
Neuroendocrine tumors (NETs) result from the abnormal growth of neoplasms that originate from cells of the various endocrine glands and nervous systems. Though most of these are benign, some tend to become malignant and may turn cancerous in the long term. Neuroendocrine tumors are generally infected firstly in intestine, which are often known as carcinoid tumors, pancreas is the second most prime organ in the body where the growth of NET is common.
The neuroendocrine tumor treatment market is expected to gain steady traction in the foreseeable future as there are many products in various pharmaceutical company product pipeline. As there is an increase in NET incidence in various geographies, there is a need for fast tract drug approval process which will bring the products in market in a very short time.
Market Dynamics
The growing incidence of GI and Lung Neuroendocrine Tumors is a key factor fueling growth of the global neuroendocrine tumor treatment market. According to a research study published by Novartis in 2015, GI Neuroendocrine comprises 61% Neuroendocrine Tumors (NET) diagnosis and 5%-44% of GI NET have advanced disease at time of diagnosis, with survival rate drastically decreasing according to severity. The 5-year survival for NET of the small intestine was 86.2%, 82.7% for stomach and 67.4% for colon. Apart from GI and Lung Neuroendocrine, there are other factors which influence the NET are hormonal imbalance at pituitary gland and thyroid gland. Rising demand for various imagining technique in North America and Europe are factors projected to fuel growth of the global market over the forecast period. Drug portfolio expansion and development of new products that can inhibit the excess hormone production, are some of the other factors augmenting growth of the global neuroendocrine tumor treatment market.
Market Taxonomy
This report segments the global neuroendocrine tumor treatment market on the basis of drug, indication, end user, and geography. On the basis of drug, the neuroendocrine tumor treatment market is categorized into Everolimus, Sunitinib Malate, Lu-Dotate, Lanreotide, and Octreotide. On the basis of indication, the neuroendocrine tumor treatment market is categorized into Gastrointestinal Neuroendocrine Tumor, Lung Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor and Others Neuroendocrine Tumor. On the basis of end-user, the neuroendocrine tumor treatment market is categorized into hospital, oncology centers, and others which includes GI centers, Cardio-thoracic centers, NET centers. For comprehensive understanding of market dynamics, the global neuroendocrine tumor treatment market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.
Key features of the study:
• This report provides in-depth analysis of the neuroendocrine tumor treatment and is its effects, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 - 2025, considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global neuroendocrine tumor treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
• Key companies covered as a part of this study include Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Applications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc.and Exelixis, Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, end user upgrades, market expansion, and marketing tactics
• The global neuroendocrine tumor treatment market report caters to various stakeholders in this industry, including investors, drug/product manufacturers, distributors and suppliers for neuroendocrine tumor treatment market, research and consulting firms, new entrants, and financial analysts
• Various strategy matrices used in analyzing the neuroendocrine tumor treatment market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
• Global Neuroendocrine Tumor Treatment Market, By Drug:
o Everolimus
o Sunitinib Malate
o Lu-Dotate
o Lanreotide
o Octreotide
• Global Neuroendocrine Tumor Treatment Market, By Indication:
o Gastrointestinal NET
o Lung NET
o Pancreatic NET
o Others NET
• Global Neuroendocrine Tumor Treatment Market, By End User:
o Hospitals
o Oncology Centers
o Others
• Global Neuroendocrine Tumor Treatment Market, By Geography:
o North America
 U.S.
 U.S. Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 U.S. Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 U.S. Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 Canada
 Canada Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Canada Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Canada Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
o Europe
 U.K.
 U.K. Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 U.K. Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 U.K. Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 Germany
 Germany Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Germany Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Germany Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 Italy
 Italy Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Italy Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Italy Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 France
 France Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 France Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 France Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 Spain
 Spain Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Spain Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Spain Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 Russia
 Russia Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Russia Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Russia Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 Rest of Europe
 Rest of Europe Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Rest of Europe Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Rest of Europe Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
o Asia-Pacific
 China
 China Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 China Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 China Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 India
 India Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 India Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 India Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 Japan
 Japan Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Japan Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Japan Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 ASEAN
 ASEAN Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 ASEAN Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 ASEAN Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 Australia
 Australia Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Australia Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Australia Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 South Korea
 South Korea Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 South Korea Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 South Korea Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 Rest of Asia Pacific
 Rest of Asia Pacific Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Rest of Asia Pacific Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Rest of Asia Pacific Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
o Latin America
 Brazil
 Brazil Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Brazil Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Brazil Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 Mexico
 Mexico Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Mexico Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Mexico Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 Rest of Latin America
 Rest of Latin America Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Rest of Latin America Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Rest of Latin America Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others

o Middle East
 GCC
 GCC Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 GCC Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 GCC Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 Israel
 Israel Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Israel Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Israel Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 Rest of Middle East
 Rest of Middle East Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Rest of Middle East Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Rest of Middle East Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
o Africa
 North Africa
 North Africa Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 North Africa Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 North Africa Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 Central Africa
 Central Africa Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 Central Africa Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 Central Africa Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
 South Africa
 South Africa Neuroendocrine Tumor Treatment Market, By Drug:
 Everolimus
 Sunitinib Malate
 Lu-Dotate
 Lanreotide
 Octreotide
 South Africa Neuroendocrine Tumor Treatment Market, By Indication:
 Gastrointestinal NET
 Lung NET
 Pancreatic NET
 Others NET
 South Africa Neuroendocrine Tumor Treatment Market, By End User:
 Hospitals
 Oncology Centers
 Others
• Company Profiles
o Pfizer Inc*
 Company Overview
 Drug Portfolio
 Financial Performance
 Key Strategies
 Recent Developments
 Future Plans
o Novartis AG
o Ispen
o Advanced Accelerator Applications
o Tarveda Therapeutics
o Progenics Pharmaceuticals, Inc.
o Hutchison Medipharma Limited
o Dauntless Pharmaceuticals Inc.
o Exelixis, Inc.
"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents
1. Research Objective and assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
? Market Definition and Scope
o Executive Summary
? Market Snippet By Drug
? Market Snippet By Indication
? Market Snippet By End User
? Market Snippet By Geography
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
? Drivers
? Supply Side Drivers
? Demand Side Drivers
? Economic Drivers
? Restraints
? Market Opportunities
o Global NET Survey
o Mergers and Acquisitions
o Marketing Strategies - Novartis, Ipsen, Pfizer
o Product Pipeline
4. Global Neuroendocrine Tumor Treatment Market, By Drugs, 2016 - 2025 (US$ Million)
o Introduction
? Market Share Analysis, 2017 and 2025 (%)
? Y-O-Y Growth Analysis, 2016 - 2025
? Segment Trends
o Everolimus
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
o Sunitinib Malate
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
o Lu-Dotate
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
o Lanreotide
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
o Octreotide
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
5. Global Neuroendocrine Tumor Treatment Market, By Indication, 2016 - 2025 (US$ Million)
o Introduction
? Market Share Analysis, 2017 and 2025 (%)
? Y-O-Y Growth Analysis, 2016 - 2025
? Segment Trends
o Gastrointestinal NET
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
o Lung NET
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
o Pancreatic NET
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
o Others NET
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
?
6. Global Neuroendocrine Tumor Treatment Market, By End User, 2016 - 2025 (US$ Million)
o Introduction
? Market Share Analysis, 2017 and 2025 (%)
? Y-O-Y Growth Analysis, 2016 - 2025
? Segment Trends
o Hospitals
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
o Oncology Centers
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
o Others (GI centers, Cardiothoracic centers, NET centers, etc.)Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2016 - 2025, (US$ Million)
7. Global Neuroendocrine Tumor Treatment Market, By Geography, 2016 - 2025 (US$ Million)
o Introduction
? Market Share Analysis, By Region, 2017 and 2025 (%)
? Y-O-Y Growth Analysis, For Regions, 2016 - 2025
o North America
? Market Share Analysis, By Country, 2017 and 2025 (%)
? Y-O-Y Growth Analysis, By Country, 2016 - 2025
? U.S.
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Canada
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
o Europe
? Market Share Analysis, By Country, 2017 and 2025 (%)
? Y-O-Y Growth Analysis, By Country, 2016 - 2025
? U.K.
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Germany
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Italy
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? France
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Spain
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Russia
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Rest of Europe
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
o Asia Pacific
? Market Share Analysis, By Country, 2017 and 2025 (%)
? Y-O-Y Growth Analysis, By Country, 2016 - 2025
? China
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? India
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Japan
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? ASEAN
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Australia
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? South Korea
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Rest of Asia Pacific
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
o Latin America
? Market Share Analysis, By Country, 2017 and 2025 (%)
? Y-O-Y Growth Analysis, By Country, 2016 - 2025
? Brazil
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Mexico
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Argentina
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Rest of Latin America
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
o Middle East
? Market Share Analysis, By Country, 2017 and 2025 (%)
? Y-O-Y Growth Analysis, By Country, 2016 - 2025
? GCC Countries
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Israel
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Rest of Middle East
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
o Africa
? Market Share Analysis, By Country, 2017 and 2025 (%)
? Y-O-Y Growth Analysis, By Country, 2016 - 2025
? Northern Africa
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? Central Africa
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
? South Africa
? Country Trends
? Market Size and Forecast, By Drug, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By Indication, 2016 - 2025 (US$ Million)
? Market Size and Forecast, By End User, 2016 - 2025 (US$ Million)
8. Competitive Landscape
o Heat Map Analysis
o Company Profiles
? Pfizer Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Novartis AG
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Ipsen
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Advanced Accelerator Applications
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Tarveda Therapeutics
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Progenics Pharmaceuticals, Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Hutchison Medipharma Limited
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Dauntless Pharmaceuticals Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Exelixis, Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
o Analyst Views
9. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 20 market data tables and 30 figures on "Neuroendocrine Tumor Treatment Market - Global forecast to 2025".
 

  • Purchase Options

  • Happy To Assist You

Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Mn Units).
Market is segmented by Product Types, Drug Class, Indication, Applications, Services Types, End-users, Distribution channel, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, pipeline Analysis, incidence rate, epidemiology analysis, prevalence rate, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, export-import analysis, trade analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.

Contact us